VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin
Completed · Phase 1/Phase 2
Conditions studied: Unspecified Adult Solid Tumor, Protocol Specific
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of VX-853 in treating patients who have solid tumors who are receiving liposomal doxorubicin.
Key facts
- Study ID
- NCT00004030
- Run by
- Georgetown University
- People needed
- 45
- Starts
- 1996-03-01
- Expected to finish
- 2001-01-01
- Last updated by the study team
- 2011-03-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Vincent T. Lombardi Cancer Research Center, Georgetown University — Washington D.C., District of Columbia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.